Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
Titel:
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
Auteur:
Wilson, Wyndham H O'Connor, Owen A Czuczman, Myron S LaCasce, Ann S Gerecitano, John F Leonard, John P Tulpule, Anil Dunleavy, Kieron Xiong, Hao Chiu, Yi-Lin Cui, Yue Busman, Todd Elmore, Steven W Rosenberg, Saul H Krivoshik, Andrew P Enschede, Sari H Humerickhouse, Rod A